Genezen to Manufacture AAV Gene Therapy for SSADH Deficiency
- Genezen will produce preclinical and cGMP clinical material for Galibra Neuroscience's GAL005, an AAV gene therapy for rare neurological disorder SSADH deficiency.
- Manufacturing will occur at Genezen's Indianapolis facility, supporting IND-enabling studies and a planned Phase 1 trial using CapX capsid technology.
Operational Impact
Genezen's Indianapolis AAV manufacturing capacity is now committed to Galibra's Phase 1 program, demonstrating the CDMO's ability to support rare-disease gene-therapy development from preclinical through early clinical stages.
Source: PharmaSource RSS
Lonza Expands Accelerated DNA-to-IND Platform to Bispecific Antibodies and Fc-Fusion Proteins
- Lonza extended its DNA-to-IND pathway to non-monoclonal antibody biologics, including bispecific antibodies, Fc-fusion proteins, and high-concentration formulations.
- The integrated program combines cell line, formulation, analytical, and manufacturing development to deliver toxicology drug substance in three months and IND readiness in six months.
Operational Impact
Lonza's expanded DNA-to-IND capability for bispecific antibodies and Fc-fusion proteins reduces preclinical-to-IND timelines to six months, enabling CDMO buyers developing complex biologics to compress development risk and accelerate clinical entry.
Source: PharmaSource RSS
Piramal Embeds Patient Centricity as Operational Decision Rule Across 15 Global Sites
- Piramal Pharma Solutions has formalized patient centricity as a company-wide operating philosophy, not marketing language, with Patient Awareness Councils at all 15 sites staffed by non-senior volunteers.
- The model uses patient impact as the primary decision filter—overriding revenue conflicts when necessary—and includes mandatory training, annual excellence awards, and CEO-level council engagement.
- Practical application includes holding shipments to resolve invoice disputes and mobilizing pandemic staffing to ensure oncology product delivery, embedding patient outcomes into operational efficiency metrics.
Operational Impact
Piramal's formalized patient-centricity framework—including site-level councils, shipment-hold authority for patient-impacting issues, and CEO engagement—signals a competitive differentiation in operational governance that may influence how biotech sponsors evaluate CDMO risk and supply-chain reliability.
Source: PharmaSource RSS